Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers

Inclusion Criteria: * 18 years of age and older, male or female, of all races and ethnicities. * Prior histologically confirmed advanced squamous cell carcinoma of the head and neck that failed standard therapy (radiation, chemotherapy, surgery). * Must have a Karnofsky performance status higher than 70%. * Measurable disease by PET-CT, defined as maximum SUV ≥4 in FDG for the tumor. * Must have a discrete tumor that is accessible for unrestricted illumination of interstitial photodynamic therapy (I-PDT). * Deemed unsuitable, by multidisciplinary tumor board, for curative treatment options such as radiotherapy, surgery, chemotherapy or a combination of these modalities. This will include patients who have exceeded the maximum radiation dose and are not candidates for re-irradiation. * Deemed likely to survive for at least 6 months. * Able and willing to provide written informed consent to participate in the study. * If a female of childbearing potential, the subject is willing to take a pregnancy test and practice strict birth control (estrogen-containing oral contraceptives or an intrauterine device) throughout the study and for 3 months after Temoporfin administration. Women who have had a hysterectomy are exempt from these requirements. * Must have blood glucose level below 250 (and preferably below 200) before FDG injection, required for PET-CT. * Willing to remain in a light-avoidance environment for a time period of at least 15 days. * Laboratory criteria: * Hematocrit \>= 33%, hemoglobin \>= 11 g/dl * Platelet count \>70.000 per microliter * BUN: 7 to 20 mg/dL * CO2 (carbon dioxide): 20 to 29 mmol/L * Creatinine: 0.8 to 1.4 mg/dL * Glucose: 64 to 128 mg/dL * Serum chloride: 101 to 111 mmol/L * Serum potassium: 3.7 to 5.2 mEq/L * Serum sodium: 136 to 144 mEq/L * Liver function test: albumin, bilirrubin (direct/conjugated), ALT (alanine transaminase), AST (aspartate transaminade), GGT (gamma glutamyl transferase), ALP (alkaline phosphatase) within normal limits * White blood count \> 3,000 per microliter or ANC \> 1500 per microliter * Serum calcium within normal limits. Exclusion Criteria: * A tumor that is too close to a major blood vessel (such as the carotid artery). * A tumor invading the skull base. * The tumor is not clearly shown on the CT image. * The location and extension of the tumor precludes an effective I-PDT. * Pregnant or has uncontrolled hyperglycemia. * Has porphyria or other diseases exacerbated by light. * With hypersensitivity to Temoporfin or to any of its excipients. * Has known allergies/hypersensitivity to porphyrins. * Has known sensitivity to the CT contrast agent. (Omnipaque) * Has poor renal function as demonstrated by serum creatinine and EGFR \<40, which would preclude the using of the CT contrast agent. * Patient with a planned surgical procedure within the next 30 days. * Has a coexisting ophthalmic disease likely to require slit-lamp examination within the next 30 days. * Patient with existing therapy with a photosensitizing agent (Temoporfin, protoporphyrin or derivatives of porphyrin). * Has received prior photodynamic therapy to the proposed treatment site within the prior 3 months. * Has distant metastasis (with the exception of single stable distant metastasis that does not decrease life expectancy to less than 6 months). * Has a childbearing potential and will not use adequate contraceptive protection. * A female that is breastfeeding. * Patient of childbearing potential who has a positive (+) urine pregnancy test. * Received treatment with an experimental drug or entered another clinical trial within the prior 30 days. * Received radiotherapy to the head and neck region within the prior 3 months. * Any disease, which is caused or exacerbated by light, including systemic lupus erythematosus, psoriasis, porphyria, actinic reticuloid or xeroderma pigmentosum. * Has been treated within the prior 30 days with a light-activated therapy or other medication that may render the subject photosensitive (e.g., psoralen ultraviolet A-range \[PUVA\], Accutane, 5-Fluorouracil, tetracycline's ). * Not willing or able to complete the visit requirements of this protocol or adhere to the instructions regarding light exposure. * Any other condition that the PI staff feels will be an endangerment to the subject.